Immunology and Infectious Diseases

Novartis has a diverse portfolio of medications for conditions that involve the immune system - including transplantation, immunology, infectious diseases, dermatology and bone health.

Our goals in infectious diseases are to:

• Address unmet health needs by finding treatments that combat life-threatening infections
• Achieve a leadership position in hepatitis, a viral infection that affects the liver
• Develop new therapies to treat bone diseases such as osteoporosis

Novartis pioneered medicines to assist organ transplantation with the discovery of cyclosporine more than 30 years ago. We have a broad portfolio of immunosuppressants, including Neoral (cyclosporine), Simulect (basiliximab), Myfortic (micophenolic acid) and Certican (everolimus).

Other leading products include Aclasta/Reclast (zoledronic acid 5 mg), a once-yearly infusion for postmenopausal women and for men suffering from osteoporosis, and Tyzeka/Sebivo (telbivudine), a therapy for chronic hepatitis B.

One of our leading development compounds, ABF656 (albuferon), targets hepatitis C and is in Phase III studies.